These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 28620691)

  • 21. YB-1: The key to personalised prostate cancer management?
    Bates M; Boland A; McDermott N; Marignol L
    Cancer Lett; 2020 Oct; 490():66-75. PubMed ID: 32681926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy.
    Berg KD; Røder MA; Thomsen FB; Vainer B; Gerds TA; Brasso K; Iversen P
    Prostate; 2015 Oct; 75(14):1499-509. PubMed ID: 26053696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Managed care implications in castration-resistant prostate cancer.
    Lew I
    Am J Manag Care; 2013 Dec; 19(18 Suppl):s376-81. PubMed ID: 24494692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Caveolin-1 as a biomarker to predict therapeutic effect of low-frequency ultrasound combined with SonoVue on prostate cancer in nude mice model.
    Xu W; Nan S; Bai W; Shen E; Hu B
    Cancer Biomark; 2014; 14(4):279-86. PubMed ID: 24934371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Longitudinal tracking of subpopulation dynamics and molecular changes during LNCaP cell castration and identification of inhibitors that could target the PSA-/lo castration-resistant cells.
    Rycaj K; Cho EJ; Liu X; Chao HP; Liu B; Li Q; Devkota AK; Zhang D; Chen X; Moore J; Dalby KN; Tang DG
    Oncotarget; 2016 Mar; 7(12):14220-40. PubMed ID: 26871947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-Resistant Prostate Cancer.
    Degeling K; Schivo S; Mehra N; Koffijberg H; Langerak R; de Bono JS; IJzerman MJ
    Value Health; 2017 Dec; 20(10):1411-1419. PubMed ID: 29241901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.
    Climent MÁ; León-Mateos L; González Del Alba A; Pérez-Valderrama B; Méndez-Vidal MJ; Mellado B; Arranz JÁ; Sánchez-Hernández A; Cassinello J; Olmos D; Carles J
    Crit Rev Oncol Hematol; 2015 Nov; 96(2):308-18. PubMed ID: 26100652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Personalization of prostate cancer therapy through phosphoproteomics.
    Yang W; Freeman MR; Kyprianou N
    Nat Rev Urol; 2018 Aug; 15(8):483-497. PubMed ID: 29752463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug discovery in advanced prostate cancer: translating biology into therapy.
    Yap TA; Smith AD; Ferraldeschi R; Al-Lazikani B; Workman P; de Bono JS
    Nat Rev Drug Discov; 2016 Oct; 15(10):699-718. PubMed ID: 27444228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.
    Yu EY; Duan F; Muzi M; Deng X; Chin BB; Alumkal JJ; Taplin ME; Taub JM; Herman B; Higano CS; Doot RK; Hartfeil D; Febbo PG; Mankoff DA
    J Nucl Med; 2015 Mar; 56(3):354-60. PubMed ID: 25635138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the adaptive molecular landscape of castration-resistant prostate cancer.
    Wyatt AW; Gleave ME
    EMBO Mol Med; 2015 Jul; 7(7):878-94. PubMed ID: 25896606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).
    Sonpavde G; Wang CG; Galsky MD; Oh WK; Armstrong AJ
    BJU Int; 2015 Jul; 116(1):17-29. PubMed ID: 25046451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer.
    Josefsson A; Linder A; Flondell Site D; Canesin G; Stiehm A; Anand A; Bjartell A; Damber JE; Welén K
    Prostate; 2017 Jun; 77(8):849-858. PubMed ID: 28295408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current, new and novel therapy for castration-resistant prostate cancer.
    Gaya JM; Ahallal Y; Sanchez-Salas R; Barret E; Rozet F; Galiano M; Macek P; Durand M; Cerruti J; Prapotnich D; Ropert S; Bennamoun M; Cathelineau X
    Expert Rev Anticancer Ther; 2013 Jul; 13(7):819-27. PubMed ID: 23875660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Using circulating tumor cells to inform on prostate cancer biology and clinical utility.
    Li J; Gregory SG; Garcia-Blanco MA; Armstrong AJ
    Crit Rev Clin Lab Sci; 2015; 52(4):191-210. PubMed ID: 26079252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current role of immunotherapy for the treatment of prostate cancer.
    Porfyris O; Kalomoiris P
    J BUON; 2013; 18(4):809-17. PubMed ID: 24344002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.
    Bitting RL; Healy P; Halabi S; George DJ; Goodin M; Armstrong AJ
    Urol Oncol; 2015 Mar; 33(3):110.e1-9. PubMed ID: 25595577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer.
    Mikah P; Krabbe LM; Eminaga O; Herrmann E; Papavassilis P; Hinkelammert R; Semjonow A; Schrader AJ; Boegemann M
    BMC Cancer; 2016 Mar; 16():214. PubMed ID: 26975660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Navigating Treatment of Metastatic Castration- Resistant Prostate Cancer: Nursing Perspectives.
    dela Rama F; Pratz C
    Clin J Oncol Nurs; 2015 Dec; 19(6):723-32. PubMed ID: 26583636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [New therapies in metastatic castration resistant prostate cancer].
    Thibault C; Massard C
    Bull Cancer; 2015 Jun; 102(6):501-8. PubMed ID: 26022286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.